Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 799 of 6351
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowIn adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16…
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New HIV prevention shots could protect breastfeeding moms and their babies
Prevention OngoingThe goal of this this hybrid safety/implementation study is to evaluate whether using long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP) is acceptable, feasible and safe in post-partum people who are breastfeeding. The main question\[s\] it aims to answer are: * Will CA…
Phase 4 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
New hope for rare ovarian cancers: drug combo trial launches
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.
Phase 2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Wireless Lung-Artery sensor could keep heart failure patients out of hospital
Disease control Recruiting nowThis is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort…
Sponsor: Endotronix, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for swallowing: drug targets esophagus scarring in EoE
Disease control OngoingThis is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New schizophrenia drug shows promise in early trial
Disease control CompletedThis is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacer…
Phase 2 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug could make stem cell transplants safer for rare immune disorder
Disease control OngoingBackground: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transplant ca…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gene therapy trial targets duchenne in toddlers
Disease control OngoingThis open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
New PET-Guided radiation aims to outsmart resistant tumors
Disease control Recruiting nowThis phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligopro…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can paxlovid hold the line against severe COVID-19 outside the lab?
Disease control Recruiting nowThe purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea. This study is seeking participants who are: * Patients with mi…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Stroke showdown: which Pre-Clot drug wins?
Disease control Recruiting nowIn patients with acute ischemic stroke secondary to large vessel occlusion, the role of intravenous adjunctive medications, such as tirofiban, or alteplase before endovascular thrombectomy has not been well investigated. This trial aim to evaluate the efficacy and safety of intra…
Phase 2/3 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can a single infusion lock in bone gains after osteoporosis treatment?
Disease control OngoingA 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab
Sponsor: 424 General Military Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New injection aims to restore swallowing in rare muscle disease
Disease control Recruiting nowSubjects who have enrolled in the oculopharyngeal muscular dystrophy (OPMD) natural history study (Study BNTC-OPMD-NH-001) and have completed at least 6 months of follow up in Study BNTC-OPMD-NH-001 may be eligible to participate in this study, where all subjects will be treated …
Phase 1/2 • Sponsor: Benitec Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could stem cells offer a lifeline for End-Stage liver disease?
Disease control CompletedThere is a rise in the prevalence of end-stage liver disease during the last decade. End-stage liver disease has become one of the leading causes of death in Western countries. Liver transplantation is the only curative treatment for patients with end-stage liver disease. However…
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
Phase 2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New stent graft could fix Life-Threatening aorta tears without open surgery
Disease control By invitation onlyThe primary objective of ARISE II is to assess the safety and effectiveness of the GORE® Ascending Stent Graft device in the treatment of lesions involving the ascending aorta and aortic arch.
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ultrasound vs. MRI: which spots hidden liver cancer better?
Diagnosis Recruiting nowThe study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-e…
Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New pacing method may outperform standard therapy in heart failure patients
Disease control Recruiting nowConduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: mortality, heart failure hospitalization or cardiac transplant (CONSYST-CRT II trial). Superiority trial that aims to study the composite endpoint consisting of all-cause mo…
Sponsor: Hospital Clinic of Barcelona • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a meditation practice curb Post-Surgery pain and opioid use?
Symptom relief Recruiting nowThe purpose of this study is to investigate the efficacy of a positive affect enhancing intervention designed to reduce pain and augment reward system function in knee osteoarthritis (KOA) patients undergoing total knee arthroplasty (TKA). The scientific premise is that patient u…
Sponsor: University of Virginia • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC